In spite of the statement by Masamha et al. [38], who, based on an experiment on A2780 and SK-OV-3 cells, showed that cyclin D1 inhibition is necessary to inhibit cell cancer growth and is a potential therapeutic target in ovarian cancer cells, we declare that both ObR blockers, by downregulating cdk2 and cdk 4, can downregulate the formation of the cyclin A/cdk2 and cyclin D/cdk4 complex and inhibit cell proliferation. This evidence concerns the gene CDK2 and ovarian carcinoma.